Agenus Raises Up to $340M on Neoadjuvant MSS Colon Cancer

Company: Agenus Event type: Financing and clinical prioritization Modality: Immuno-oncology antibody combination Assets: Botensilimab plus balstilimab Disease area: Microsatellite-stable colon cancer and colorectal cancer Insilens signal strength: 4 / 5 Summary Agenus announced an oversubscribed private placement that could provide up to $340 million to…